P4–277: Evaluation of beta‐amyloid‐lowering efficacy of a novel BACE1 inhibitor in multiple species
Charles E. Nolan(Pfizer (United States)), David Riddell(Eli Lilly (United States)), Cathleen Gonzales, Andre Negahban(Pfizer (United States)), Stephen Noell(Pfizer (United States)), Shawn D. Doran(Pfizer (United States)), Claude Ambroise(Pfizer (United States)), Leslie R. Pustilnik(Pfizer (United States)), Kevin Atchison(Merck & Co., Inc., Rahway, NJ, USA (United States)), Ashley Robshaw(Pfizer (United States)), Feng Pan(Hong Kong Polytechnic University), Christine Oborski(ProterixBio (United States)), Jianhua Liu(Shanghai Jiao Tong University), Christopher R. Butler(Pfizer (United States)), Cheng Chang(National University of Singapore), Brian T. O’Neill(Pfizer (United States)), Elizabeth M. Beck(Pfizer (United States)), Éva Hajós‐Korcsok(Pfizer (United States)), Yasong Lu(Pfizer (United States)), Michael A. Brodney(Vertex Pharmaceuticals (United States))
Cited by 0
Related Papers
ApoE Promotes the Proteolytic Degradation of Aβ
|Neuron|2008|869
Application of the Bicyclo[1.1.1]pentane Motif as a Nonclassical Phenyl Ring Bioisostere in the Design of a Potent and Orally Active γ-Secretase Inhibitor
|Journal of Medicinal Chemistry|2012|460
Tau molecular diversity contributes to clinical heterogeneity in Alzheimer’s disease
|Nature Medicine|2020|445
Impact of Apolipoprotein E (ApoE) Polymorphism on Brain ApoE Levels
|Journal of Neuroscience|2008|351
Compartmentalization of β-secretase (Asp2) into low-buoyant density, noncaveolar lipid rafts
|Current Biology|2001|302